Firma 4SC, Autor bei PR-Web

4SC AG: Conference call to be hosted on 20 April 2021 to present the Q1 report 2021

Posted on 13. April 2021 by Firma 4SC Posted in General Tagged 4sc, access, any, conference, control, document, financial, management, phone, press, prior, release, report, risks, statements

4SC AG (4SC, FSE Prime Standard: VSC) will publish its Q1 report 2021 on 20 April 2021. On this day, the Management of 4SC AG will host a conference call at 2 pm CEDT (8 am EDT) to inform about important […]

4SC to present at the Virtual European Biotech Investor Days 2021 Conference

Posted on 8. April 2021 by Firma 4SC Posted in Research / Development Tagged 4sc, any, Bank, based, biotech, conference, control, press, release, risks, statements, such, these, virtual, wave

4SC AG (4SC, FSE Prime Standard: VSC) CEO Dr. Jason Loveridge will attend and present at the Goodwin, Solebury Trout, Deutsche Bank and Nasdaq European Biotech Investor Days 2021, a virtual conference highlighting the next wave of biotech opportunities coming out […]

4SC & Immunic Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Posted on 31. March 202131. March 2021 by Firma 4SC Posted in General Tagged 4sc, any, clinical, company, dhodh, immunic, immunic's, imu, inflammatory, payment, risks, royalty, statements, transaction, with

4SC AG (FSE Prime Standard: VSC), and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of an agreement under which […]

4SC AG provides results for financial year 2020 and outlook for 2021

Posted on 23. March 2021 by Firma 4SC Posted in General Tagged 4sc, avelumab, cancer, ctcl, domatinostat, forecast, mcc, merck, merklin, patients, resmain, resminostat, statements, thousand, with

4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 2020, presenting all material reporting period developments and provides an outlook for 2021. The full report is available at http://www.4sc.com/investors/investor-information/financial-reports/. Key highlights […]

4SC AG: 4SC AG resolves to issue new shares with expected proceeds of approx. EUR 7.5 million

Posted on 26. November 2020 by Firma 4SC Posted in General Tagged 4sc, 4sc's, clinical, domatinostat, expected, injection, jurisdiction, new, par, para, resminostat, securities, statements, supervisory, with

The management board of 4SC AG ("4SC") (4SC, FSE Prime Standard: VSC) today resolved – with the approval of the supervisory board – to implement a capital increase to raise funds to continue to advance its drug development programs. In […]

4SC AG: First Patient Enrolled in MERKLIN 2 Study

Posted on 21. October 2020 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, axitinib, bavencio, cancer, domatinostat, hepatitis, honor, hypothyroidism, merck, merklin, patients, pediatric, statements, with

Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in Merkel cell carcinoma (MERKLIN 2 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that the first patient has been enrolled in the MERKLIN […]

4SC provides Q3 business update and outlook

Posted on 20. October 2020 by Firma 4SC Posted in General Tagged 4sc, avelumab, bavencio, domatinostat, forecast, kv13, maruho, merck, merklin, patients, resmain, resminostat, statements, thousand, with

4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2020, as well as its current outlook. The full report is available for download on 4SC’s website. Key highlights of Q3 […]

4SC AG announces availability of a new publication on domatinostat

Posted on 12. October 2020 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, cancer, cell, cells, domatinostat, esmo, hdac, hla, mcc, merklin, monotherapy, patients, statements, with

4SC AG (4SC, FSE Prime Standard: VSC) today announced the availability of a new publication on domatinostat in the Journal of Investigative Dermatology entitled "The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell […]

4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer

Posted on 6. October 2020 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, cancer, cells, domatinostat, esmo, hdac, microsatellite, monotherapy, nhs, patients, research, statements, unresectable, with

4SC AG (4SC, FSE Prime Standard: VSC) today announced, that the Safety Review Committee consisting of clinical and drug safety experts evaluated the safety data from the third and final dose cohort and recommended continuation into the expansion phase of […]

4SC AG: 4SC AG announces publication of a new article on domatinostat

Posted on 28. September 2020 by Firma 4SC Posted in General Tagged 4sc, avelumab, cancer, cell, cells, domatinostat, esmo, hdac, microsatellite, monotherapy, nhs, patients, research, statements, with

4SC AG (4SC, FSE Prime Standard: VSC) today announced the publication of a new article in Research Outreach, Health & Medicine authored by its Head of Research and Translational Medicine Svetlana Hamm Ph.D entitled "A New Weapon to Boost Cancer […]